Top 50 most influential people on Stem Cells today terrapinn.com/ TOP 50 stem cell influencers terrapinn.com/loyaltyasia Who are the most influential people in stemcell the global stem cell and cell therapy field? This is the question we asked our blog subscribers, LinkedIn group members and anyone in our contact network to compile a comprehensive list of the Top 50 as named by you. The following 50 personalities were picked based on their career achievements whether this was groundbreaking discovery and research or innovation, funding, lifetime dedication or simply because they might have inspired others to do well. It is great to see that we have representatives from all aspects including industry, governments, philanthropy, academia and even showbiz. Thank you to everyone who has helped us compile the list and please feel free to share it with your colleagues. blogs.terrapinn.com/ TOP 50 stem cell influencers 50 49 48 terrapinn.com/loyaltyasia totalbiopharma No. 50 Paul Knoepfler Dr Catherine Prescott Michael Werner Associate Professor Owner Partner UC Davis School of Medicine Biolatris Holland and Knight Cathy brings over 20 years of experience in [email protected] Werner has more than 25 years of Dr Paul Knoepfler is an Associate Professor in research, management and business within healthcare law, lobbying, policy Cell Biology and Human Anatomy at the UC the life-science and venture capital sectors. development and regulatory experience in Davis School of Medicine, where his lab studies She is the Founder Director of Biolatris Ltd., Washington. In addition to forming the stem cells and cancer. He is also a faculty Co-founder and Director of UniverCELL Market Alliance for Regenerative Medicine and member of the UC Davis Genome Center and , Chair of the UK National Stem Cell Network serving as its Executive Director, he is also a leader of the Cancer Stem Cell Initiative at the Advisory Committee, Director of the EESCN partner at the law firm Holland & Knight, UCD Comprehensive Cancer Center. He also Life Sciences Advisory Board member for the LLP. teaches graduate courses in stem cells and is an Worcester Polytechnic Institute (MA, USA) and instructor for the histology course at UCD School Advisory Committee member for the charity He focuses on issues affecting biotechnology of Medicine. He is a cancer survivor, patient DebRA. Cathy is experienced in technology and pharmaceutical companies, researchers advocate, writer, and is currently the only assessment, market positioning, business and research institutions, health care faculty level academic blogger on stem cell development, strategic planning, raising investors, physicians, and patients with research in the world. venture funds and private investment. She is a particular expertise in regenerative recognised opinion leader within the stem cell medicine. and regenerative medicine business sector. TOP 50 stem cell influencers terrapinn.com/ 47 46 45 terrapinn.com/loyaltyasia stemcell Eduardo Bravo Dr Christian Schneider Ram Mandalam Chief Executive Officer Chair President and Chief Executive TiGenix CAT, European Medicines Officer Agency Cellerant Therapeutics Mr. Bravo has more than 20 years Dr. med. Christian K Schneider is Senior Ram Mandalam, joined the company in experience in the pharmaceutical industry. Medical Officer at the Danish Health and 2005. Ram was previously Executive He held several senior management Medicines Authority (formerly the Danish Director of Product Development at Geron positions at Sanofi-Aventis, including Vice Medicines Agency) since 2011. At the Corporation, where he managed the President for Latin America, a division with European Medicines Agency, he is the development and manufacturing of cell 2000 employees and sales of more than €1 Chairman of the Committee for Advanced based therapies for treatment of billion. At Sanofi-Aventis he also held senior Therapies (CAT) since 2009, and also the degenerative diseases and cancer. Prior to positions in Marketing and Sales for Europe Chairman of the CHMP Working Party on Geron, he was Director of Developmental and he was General Manager for Belgium. Similar Biological (Biosimilar) Medicinal Research at Aastrom Biosciences, where he Prior to his tenure at Sanofi-Aventis, Mr. Products. Between September 2007 and July was responsible for the research and Bravo was for 7 years at SmithKline 2011, he was a member of the Committee for development programs involving ex vivo Beecham in sales positions both nationally Medicinal Products for Human Use (CHMP), expansion of human bone marrow stem and internationally. Mr. Bravo holds a co-opted for the area of Advanced Therapies cells and dendritic cells. Dr. Mandalam degree in Business Administration and an – Gene, Cell and Tissue Therapies. received his Ph.D. in Chemical Engineering MBA (INSEAD), and is co-Chair of the from the University of Michigan. Alliance of Advanced Therapies. blogs.terrapinn.com/ TOP 50 stem cell influencers 44 43 42 terrapinn.com/loyaltyasia totalbiopharma Dr Alan Lewis Dr Paul Laikind Susan Solomon Chief Executive Officer Chief Executive Officer Chief Executive Officer Medistem ViaCyte New York Stem Cell Dr Lewis is currently a Management Paul K. Laikind, has over 25 years of Foundation Consultant to various specialty leadership experience in the biotechnology Susan L. Solomon is Chief Executive Officer biopharmaceutical companies. He was most and life sciences industry in San Diego. A and Co-Founder of The New York Stem Cell recently President, CEO and Chariman of serial entrepreneur, Dr. Laikind co-founded Foundation (NYSCF), a non-profit Ambit BioSciences, and previously President and held top executive positions at three San organization established in 2005 to and CEO of the Juvenile Diabetes Research Diego companies that each went public accelerate cures through stem cell research. Foundation and President, CEO and Director before ultimately being acquired. These of Novocell, Inc. include Gensia Pharmaceuticals, Inc., A longtime health-care advocate, Ms. Viagene, Inc., which, like Gensia, was Solomon is a founding member and current Dr. Lewis currently serves as a Director of founded upon technology Dr. Laikind helped President of NYAMR (New Yorkers for the BioMarin Pharmaceutical, Inc., and BIOCOM. to create, and, most recently, Metabasis Advancement of Medical Research), is on the He holds a Ph.D. in pharmacology from the Therapeutics, Inc. where he served as Executive Committee for the Alliance for University of Wales in Cardiff and completed President and Chief Executive Officer Regenerative Medicine, and she has been a his postdoctoral training at Yale University. member of the Board of Directors of the Dr. Laikind holds a B.S. in Biochemistry from Juvenile Diabetes Research Foundation, New the University of California, Davis, and a York Chapter. Ms. Solomon was also a Ph.D. in biochemistry from the University of member of the Strategic Planning Committee California, San Diego. of the Empire State Stem Cell Board. TOP 50 stem cell influencers terrapinn.com/ 41 40 39 terrapinn.com/loyaltyasia stemcell Dr Gael Margolin Fred Gage Dr Jan Nolta Chief Executive Officer Professor, Laboratory of Stem Cell Program Director Gamida Cell Genetics UC Davis Salk Institute Dr Nolta is the Director of the Stem Cell Dr. Margolin is the president and CEO of Fred H. Gage, a professor in the Laboratory Program at UC Davis School of Medicine, and Gamida Cell. Prior to joining the company, of Genetics, concentrates on the adult directs the new Institute for Regenerative Dr. Margolin served as vice president of central nervous system and unexpected Cures. The current research in Dr. Nolta’s Denali Ventures LLC, where she specialized plasticity and adaptability to environmental laboratory is focused on developing in investments in pharmaceutical and stimulation that remains throughout the therapies that will use mesenchymal stem biotechnology companies. Dr. Margolin also life of all mammals. His work may lead to cells (MSCs) to deliver factors for treating worked at Teva Pharmaceuticals, where she methods of replacing or enhancing brain Huntington’s disease and other disorders was responsible for new product initiatives, and spinal cord tissues lost or damaged due and injuries. Her group focuses on “bench to evaluation of investment opportunities for to Neurodegenerative disease or trauma. the bedside” research, and she has been the R&D division, and multiple drug involved in numerous clinical trials of gene development programs. Dr. Margolin holds a His work may lead to methods of replacing and cell therapy. She is scientific director of Ph.D. in Biology from the Weizmann Institute brain tissue lost to stroke or Alzeimers the new Good Manufacturing Practice clean of Science and was a post-doctoral associate Disease and repairing spinal cordsdamaged room facility at UC Davis, where stem cells of at the Yale University School of Medicine. by trauma. He is the President-elect of the different types are being isolated or ISSCR. expanded for clinical trials. blogs.terrapinn.com/ TOP 50 stem cell influencers 38 37 36 terrapinn.com/loyaltyasia totalbiopharma Keith Murphy Dr Robert Preti Anthony Atala Chairman and Chief Executive Co-Founder, President and Director Read Bio Officer Read Bio CSO Institute for Regenerative Organovo Progenitor Cell Therapy Medicine, Wake Forest Keith Murphy has more than 17 years of Robert “Bob” Preti, PhD, is the co-founder, Anthony Atala, M.D., is the Director of the experience in biotechnology, including President, and Chief Scientific Officer of PCT. Wake Forest Institute for Regenerative serving in Product Strategy and Director of Following the acquisition of PCT by NeoStem Medicine, and the W.H. Boyce Professor Process Development roles at Amgen. His 10 Inc. in January 2011, he has also been and Chair of the Department of Urology at years at Amgen included four years as Global directing the development and expansion of Wake Forest University. Operations Leader for the largest NeoStem’s cell therapy pipeline, as well as development program in Amgen’s history, participating in setting NeoStem’s strategic Dr. Atala is a practicing surgeon and a Phase 3 osteoporosis/bone cancer drug direction.